Modeling Pharmacokinetic Profiles for Assessment of Anti-Cancer Drug on a Microfluidic System

被引:8
|
作者
Guo, Yaqiong [1 ,2 ]
Deng, Pengwei [1 ,2 ]
Chen, Wenwen [1 ,2 ]
Li, Zhongyu [1 ,3 ]
机构
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Div Biotechnol, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100190, Peoples R China
[3] Dalian Minzu Univ, Coll Life Sci, Dalian 116600, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
microfluidics; intestine; drug; pharmacokinetic (PK) profile; CHIP; METABOLISM; ORGANS; TOXICITY; PLATFORM; TISSUES; CELLS;
D O I
10.3390/mi11060551
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The pharmacokinetic (PK) properties of drug, which include drug absorption and excretion, play an important role in determining the in vivo pharmaceutical activity. However, current in vitro systems that model PK profiles are often limited by the in vivo-like concentration profile of a drug. Herein, we present a perfused and multi-layered microfluidic chip system to model the PK profile of anti-cancer drug 5-FU in vitro. The chip device contains two layers of culture channels sandwiched by a porous membrane, which allows for drug exposure and diffusion between the two channels. The integration of upper intestine cells (Caco-2) and bottom targeted cells within the device enables the generation of loading and clearance portions of a PK curve under peristaltic flow. Fluorescein as a test molecule was initially used to generate a concentration-time curve, investigating the effects of parameters of flow rate, administration time, and initial concentration on dynamic drug concentration profiles. Furthermore, anti-cancer drug 5-FU was performed to assess its pharmaceutical activity on target cells (human lung adenocarcinoma cells or human pulmonary alveolar epithelial cells) using different drug administration regimens. A dynamic, in vivo-like 5-FU exposure refers to PK profile regimen, led to generate a lower drug concentration (dynamically fluctuate from 0 to 1 mu g/mL affected by absorption) compared to the constant exposure. Moreover, the PK profile regimen alleviates the drug-induced cytotoxicity on target cells. These results demonstrate the feasibility of determining the PK profiles using this microfluidic system with in vivo-like drug administration regimens. This established system may provide a powerful platform for the prediction of drug safety and effectiveness in the pharmaceutical research.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] FTORAFUR - NEW ANTI-CANCER DRUG
    BRENNER, H
    CHAITCHIK, S
    BRENNER, J
    DIGESTION, 1977, 16 (03) : 233 - 233
  • [32] CISPLATIN - NEW ANTI-CANCER DRUG
    ROZENCWEIG, M
    ABELE, R
    BEDOGNI, P
    KENIS, Y
    LOUVAIN MEDICAL, 1979, 98 (10): : 679 - 684
  • [33] Mitosis as an anti-cancer drug target
    Salmela, Anna-Leena
    Kallio, Marko J.
    CHROMOSOMA, 2013, 122 (05) : 431 - 449
  • [34] Modeling of Anti-Cancer Drug Release Kinetics From Liposomes and Micelles: A Review
    Al Sawaftah, Nour
    Paul, Vinod
    Awad, Nahid
    Husseini, Ghaleb A.
    IEEE TRANSACTIONS ON NANOBIOSCIENCE, 2021, 20 (04) : 565 - 576
  • [35] COMPLEXT PATIENT DERIVED ORGANOIDS(CPDOS) MODELING FOR ANTI-CANCER DRUG SCREENING
    Li, Ling
    Knutsdottir, Hildur
    Hui, Ken
    Weiss, Matthew J.
    He, Jin
    Philosophe, Benjamin
    Cameron, Andrew
    Wolfgang, Christopher L.
    Pawlik, Timothy M.
    Ghiaur, Gabriel
    Ewald, Andrew
    Mezey, Esteban
    Bader, Joel
    Selaru, Florin
    GASTROENTEROLOGY, 2019, 156 (06) : S1508 - S1508
  • [36] Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues
    Kim, MunJu
    Gillies, Robert J.
    Rejniak, Katarzyna A.
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [37] Investigation of Zinc Oxide Nanoparticles as Anti-cancer Drug Delivery System
    Nadeem, Kizilbash
    Jamal, Alruwaili
    RESEARCH JOURNAL OF BIOTECHNOLOGY, 2021, 16 (04): : 39 - 43
  • [38] METFORMIN - FROM ANTI-DIABETIC DRUG TO ANTI-CANCER DRUG
    Markowicz-Piasecka, Magdalena
    Huttunen, Kristiina M.
    Mikiciuk-Olasik, Elzbieta
    Mateusiak, Lukasz
    Sikora, Joanna
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (01): : 3 - 18
  • [39] Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles
    Li, Xiangyi
    Xu, Yingjie
    Cui, Hui
    Huang, Tao
    Wang, Disong
    Lian, Baofeng
    Li, Wei
    Qin, Guangrong
    Chen, Lanming
    Xie, Lu
    ARTIFICIAL INTELLIGENCE IN MEDICINE, 2017, 83 : 35 - 43
  • [40] Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses
    Yao, Ye
    Yao, Qingyu
    Fu, Yu
    Tian, Xiuyun
    An, Qiming
    Yang, Liang
    Su, Hong
    Lu, Wei
    Hao, Chunyi
    Zhou, Tianyan
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (02) : 1169 - 1177